US75615P1030 - Common Stock
REATA PHARMACEUTICALS INC-A
NASDAQ:RETA (9/25/2023, 7:12:09 PM)
After market: 172.4 +0.04 (+0.02%)172.36
+0.04 (+0.02%)
Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. The company is headquartered in Plano, Texas and currently employs 321 full-time employees. The company went IPO on 2016-05-26. The firm concentrates on small-molecule therapeutics with mechanisms of action for the treatment of severe, life-threatening diseases with few or no approved therapies. The firm's first product, SKYCLARYS (omaveloxolone), is used for the treatment of Friedreich's ataxia (FA) in adults and adolescents aged 16 years and older. The company is also engaged in developing cemdomespib, the lead product candidate from its Hsp90 modulator program, in neurological indications and Nrf2 activators for neurological diseases. Omaveloxolone activates the transcription factor Nrf2 to normalize mitochondrial function, restore redox balance, and resolve inflammation, in nonclinical models. Its Nrf2 activators are applicable to both rare diseases, such as Huntington's disease, progressive supranuclear palsy, frontotemporal dementia, primary progressive multiple sclerosis, and others.
REATA PHARMACEUTICALS INC-A
5320 Legacy Dr
Plano TEXAS 75024
P: 19728652219.0
CEO: J. Warren Huff
Employees: 321
Website: https://www.reatapharma.com/
Reata Pharmaceuticals (RETA) said that its shareholders approved its previously disclosed acquisition by Biogen (BIIB) at a special meeting on Thursday. Read more here.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Here you can normally see the latest stock twits on RETA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: